Reading list
Sensitivity, movement and hormone papers
The papers gathered together, with their own titles intact.
Sensitivity, surgery and emesis
For the site’s starting question, there is the rat visceral-and-somatic sensitivity experiment. The adult bowel-resection trial supplies the clinical disappointment that matters to the movement story. The ferret cisplatin study gives weight preservation and vomiting separate answers.
The endocrine papers explain why a compound introduced through growth-hormone release appears in this company. One item further below concerns GSK894281, a different ghrelin-receptor agonist tested in rats; that toxicology finding is discussed with its identity attached on the hormone page.
- Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics ↗
- Ipamorelin, the first selective growth hormone secretagogue ↗
- Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus ↗
- Actions and therapeutic pathways of ghrelin for gastrointestinal disorders ↗
- Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients ↗
- The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism ↗
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers ↗
- Integrated approach to early detection of cardiovascular toxicity induced by a ghrelin receptor agonist ↗